William Tanner was terminated as Chief Financial Officer at CervoMed Inc..
“Dr. Tanner’s employment with the Company will terminate effective May 31, 2024, and, effective June 1, 2024, Dr. Tanner will begin service as a consultant to the Company.”
CervoMed Inc. — fact timeline
Source-grounded facts extracted from CervoMed Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
William Elder was appointed as Chief Financial Officer at CervoMed Inc..
“appointed William Elder, the Company’s current General Counsel, Corporate Secretary and Acting Principal Financial Officer, to serve as the Company’s Chief Financial Officer, effective June 1, 2024.”
CervoMed Inc. reported first quarter ended March 31, 2024 results: net income approximately $2.5 million.
“Net income was approximately $2.5 million for the three months ended March 31, 2024”
CervoMed Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2023. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.”
CervoMed Inc. entered into Purchase Agreement with purchasers named therein valued at approximately $50 million (effective 2024-03-28).
“On March 28, 2024, CervoMed Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of an aggregate of 2,532,285 units”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.